Key result
Discharge PtfV1(+) is linked to ~86% higher major cardiovascular events risk in unstable angina.
Why the study?
Although PtfV1 irregularity is linked to diverse cardiovascular diseases, its prognostic significance in unstable angina has not been extensively studied.
Does PtfV1 positivity at discharge predict major adverse cardiovascular events in patients with unstable angina?
Cohort (n=707)
No
Does PtfV1 positivity at discharge predict major adverse cardiovascular events in patients with unstable angina?
Answers are grounded in this paper and cite their sources.
PtfV1(+) may identify higher-risk unstable angina patients; hypothesis-generating for risk stratification and requires prospective validation.
Background: P-wave terminal force in lead V1 (PtfV1) irregularity has been associated with various cardiovascular conditions, including atrial fibrillation, left ventricular diastolic dysfunction, valvular heart disease, congestive heart failure, stroke, and mortality. However, its prognostic value for unstable angina (UA) has not been extensively studied. To address this knowledge gap, this study aimed to evaluate the long-term predictive significance of PtfV1 at discharge for UA patients. Methods: A total of 707 patients with newly diagnosed UA were included in this study. PtfV1 measurements were recorded at admission and discharge. PtfV1(+) was defined as an absolute value above 0.04mm·s, while PtfV1(-) was defined as an absolute value below 0.04mm·s. Based on their PtfV1 values at discharge, patients were categorized into two groups: PtfV1(-) and PtfV1(+). Univariate and multivariate regression analyses were conducted to identify variables that could potentially contribute to the risk of UA. Results: Univariate analysis revealed a higher incidence of total adverse outcomes and major adverse cardiovascular events (MACE) in the PtfV1(+) group compared to the PtfV1(-) group, with a risk ratio (RR) of 2.006 [95% confidence interval (95% CI): 1.389-2.896] for total outcomes and an RR of 2.759 (95% CI: 1.870-4.070) for MACE. After adjusting for confounding factors through multivariate analysis, participants with PtfV1(+) had a 46% increased risk [adjusted hazard ratio (HR): 1.458; 95% CI: 1.010-2.104]for total adverse outcomes and an 86% increased risk (adjusted HR: 1.863; 95% CI: 1.246-2.786) for MACE compared to those with PtfV1(-). Conclusion: The presence of PtfV1(+) at discharge is an independent predictor of poor outcomes and provides extended prognostic information for UA patients.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2023) conducted a cohort in Unstable Angina (n=707). PtfV1(+) at discharge vs. PtfV1(-) at discharge was evaluated on Major adverse cardiovascular events (MACE) (HR 1.863, 95% CI 1.246-2.786, p=<0.05). Patients with unstable angina and PtfV1(+) at discharge had an 86% increased risk of major adverse cardiovascular events compared to those with PtfV1(-).
Synapse has enriched 10 related papers. Consider them for comparative context: